Sorrento Therapeutics Inc SRNE:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
after hours iconAfter Hours: Last | 05/26/22 EDT
1.54UNCH (UNCH)
Volume
60,357
Close
1.54UNCH (UNCH)
Volume
5,545,558
52 week range
1.15 - 11.07
Loading...
  • Open1.45
  • Day High1.57
  • Day Low1.41
  • Prev Close1.44
  • 52 Week High11.07
  • 52 Week High Date07/01/21
  • 52 Week Low1.15
  • 52 Week Low Date05/12/22

Key Stats

  • Market Cap598.98M
  • Shares Out388.95M
  • 10 Day Average Volume7.80M
  • Dividend-
  • Dividend Yield-
  • Beta2.43
  • YTD % Change-66.88

KEY STATS

  • Open1.45
  • Day High1.57
  • Day Low1.41
  • Prev Close1.44
  • 52 Week High11.07
  • 52 Week High Date07/01/21
  • 52 Week Low1.15
  • 52 Week Low Date05/12/22
  • Market Cap598.98M
  • Shares Out388.95M
  • 10 Day Average Volume7.80M
  • Dividend-
  • Dividend Yield-
  • Beta2.43
  • YTD % Change-66.88

RATIOS/PROFITABILITY

  • EPS (TTM)-1.56
  • P/E (TTM)-0.99
  • Fwd P/E (NTM)-3.58
  • EBITDA (TTM)-410.587M
  • ROE (TTM)-205.97%
  • Revenue (TTM)57.03M
  • Gross Margin (TTM)72.99%
  • Net Margin (TTM)-827.29%
  • Debt To Equity (MRQ)67.55%

EVENTS

  • Earnings Date08/07/2022(est)
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Sorrento Therapeutics Inc

There is no recent news for this security.

Profile

MORE
Sorrento Therapeutics, Inc. is a clinical-stage, antibody-centric, biopharmaceutical company developing therapies to treat cancers and COVID-19. The Company’s segments include Sorrento Therapeutics and Scilex. Sorrento Therapeutics segment is organized around Immune-Oncology therapeutic area, leveraging its G-MAB antibody library and targeted delivery modalities to generate cancer therapeutics. The Scilex segment is largely organized around its non-opioid pain management...
Henry Ji Ph.D.
Chairman of the Board, President, Chief Executive Officer, Co-Founder
Elizabeth Czerepak
Chief Financial Officer, Executive Vice President
Address
4955 Directors Pl
San Diego, CA
92121-3836
United States

Top Peers

SYMBOLLASTCHG%CHG
ANAB
AnaptysBio Inc
18.96-0.23-1.20%
KNSA
Kiniksa Pharmaceuticals Ltd
7.91-0.23-2.83%
TBPH
Theravance Biopharma Inc
8.91-0.07-0.78%
ADCT
ADC Therapeutics SA
7.26+0.10+1.40%
MRUS
Merus NV
13.98-0.83-5.60%